Pfizer Inc.’s EPS Growth at a glance
Pfizer Inc. reports eps growth of 278.2% for Dec 2024. The prior period recorded -93.3% (Dec 2023). Year over year the metric moved +371.4 pts (+398.2%). The rolling three-period average stands at 75.4%. Data last refreshed Dec 7, 2025, 2:46 AM.
Latest reading
278.2% · Dec 2024
YoY movement
+371.4 pts (+398.2%)
Rolling average
75.4%
Current EPS Growth
278.2%
+371.4 pts
+398.2%
Rolling average
75.4%
Latest Value
278.2%
Dec 2024
YoY Change
+371.4 pts
Absolute
YoY Change %
+398.2%
Rate of change
3-Period Avg
75.4%
Smoothed
Narrative signal
Pfizer Inc.’s eps growth stands at 278.2% for Dec 2024. Year-over-year, the metric shifted by +371.4 pts, translating into a +398.2% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How eps growth shapes Pfizer Inc.'s story
As of Dec 2024, Pfizer Inc. reports eps growth of 278.2%. Review EPS trajectory, compounding pace, and earnings momentum supported by trailing annual filings.
Understanding EPS momentum
Sustained positive EPS growth underpins long-term shareholder returns. Volatility often reflects cyclical businesses or share-count changes.
Check the drivers behind EPS
Analyze revenue growth, margin expansion, and buybacks to see which levers are powering EPS gains.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
65.8%
Operating Margin
25.9%
Net Profit Margin
12.6%
Return on Equity
9.1%
Return on Assets
3.8%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Pfizer Inc. (PFE) FAQs
Answers tailored to Pfizer Inc.’s eps growth profile using the latest Financial Modeling Prep data.
What is Pfizer Inc.'s current eps growth?
As of Dec 2024, Pfizer Inc. reports eps growth of 278.2%. This reading reflects the latest filings and price data for PFE.
How is Pfizer Inc.'s eps growth trending year over year?
Year-over-year, the figure shifts by +371.4 pts (+398.2%). Pair this context with revenue growth and free cash flow signals to gauge momentum for PFE.
Why does eps growth matter for Pfizer Inc.?
Earnings-per-share growth reveals how quickly per-share net income is expanding or contracting versus the prior year. For Pfizer Inc., operating within Healthcare — Drug Manufacturers - General, tracking this metric helps benchmark management's execution against close competitors.
Is Pfizer Inc.'s eps growth above its recent average?
Pfizer Inc.'s rolling three-period average sits at 75.4%. Comparing the latest reading of 278.2% to that baseline highlights whether momentum is building or fading for PFE.
How frequently is Pfizer Inc.'s eps growth refreshed?
Data for PFE was last refreshed on Dec 7, 2025, 2:46 AM and updates automatically every 24 hours, keeping your valuation inputs current.